# IRF1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- IRF1 is a transcription factor crucial for innate and adaptive immunity, induced by interferons, PAMPs, and DNA damage, and it binds to ISRE and GAS-like elements to regulate genes involved in antigen presentation, antiviral defense, and programmed cell death.
- The *IRF1* gene, located at 5q23.3-q31.1, has a promoter with STAT1, ISRE-like, and NF-κB binding sites, and its transcription is epigenetically regulated by menin and RNF20, with dynamic chromatin accessibility controlled by IRF1 itself.
- IRF1's structure includes an N-terminal DNA-binding domain, a central linker with nuclear localization signals, and a C-terminal regulatory domain subject to phosphorylation, ubiquitination (by UBE3A), SUMOylation, and ADP-ribosylation (by PARP7), all modulating its stability and activity.
- IRF1 acts as a tumor suppressor by inducing cell cycle arrest (via p21), apoptosis, pyroptosis, and ferroptosis, and it is essential for MHC class I antigen presentation by upregulating HLA genes, B2M, TAP1/2, and NLRC5.
- Loss or functional inactivation of IRF1 is observed in various cancers (leukemia, breast, pancreatic, melanoma), while its sustained activation contributes to inflammatory diseases (RA, IBD, atherosclerosis) and viral infections (SARS-CoV-2, influenza) by modulating immune responses and metabolic pathways.
- Therapeutic strategies aim to activate IRF1 for cancer therapy (e.g., IFN-γ, HDAC inhibitors, PARP7 inhibitors) or inhibit it for inflammatory conditions, with pharmacogenomic considerations for its role in immunotherapy response and drug repurposing opportunities.

---

## Executive Summary & Key Metadata

Interferon Regulatory Factor 1 (IRF1) is the founding member of the interferon regulatory factor (IRF) family of transcription factors. Initially identified in 1988 for its role in virus-induced activation of the human interferon-beta (IFN-β) gene, IRF1 has since been recognized as a master regulator of innate and adaptive immunity, oncogenesis, inflammation, and programmed cell death. Unlike many of its family members, IRF1 is constitutively expressed at low levels in most cell types and is rapidly and potently induced by interferons (IFNs), cytokines, pathogen-associated molecular patterns (PAMPs), and DNA damage. Its activity is tightly regulated at the transcriptional, post-transcriptional, and post-translational levels, reflecting its central role in balancing protective immunity against immunopathology.

IRF1 functions as a sequence-specific DNA-binding transcription factor that recognizes the Interferon-Stimulated Response Element (ISRE) and the Interferon-Gamma Activated Sequence (GAS)-like elements. It governs the expression of hundreds of target genes involved in antigen presentation, antiviral defense, cell cycle arrest, apoptosis, pyroptosis, and metabolic reprogramming. Clinically, IRF1 is a well-established tumor suppressor whose loss or functional inactivation is observed in multiple malignancies, including leukemia, breast cancer, pancreatic cancer, and melanoma. Conversely, its sustained activation contributes to chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis. The dual nature of IRF1—as both a guardian of genomic integrity and a driver of inflammatory pathology—makes it a compelling yet challenging therapeutic target.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | IRF1 |
| **UniProt Accession** | P10914 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 5q23.3-q31.1 (human) [1] |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; regulates interferon-stimulated genes (ISGs), MHC class I antigen presentation, apoptosis, and cell cycle |
| **Disease & Pathology Associations** | Tumor suppressor in multiple cancers; implicated in autoimmune diseases (SLE, RA, celiac disease), inflammatory bowel disease, atherosclerosis, viral infections (SARS-CoV-2, influenza), and neurodegenerative disorders |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *IRF1* gene is located on the long arm of chromosome 5, specifically at cytogenetic band 5q23.3-q31.1 [1]. This locus was first mapped by Itoh et al. (1991) using fluorescence in situ hybridization and somatic cell hybrid panels, which localized the gene to a region frequently deleted in various human cancers, particularly myeloid leukemias and certain solid tumors [1]. The gene spans approximately 6.5 kilobases (kb) of genomic DNA and consists of 10 exons and 9 introns. The coding sequence is distributed across exons 2 through 10, with exon 1 containing the 5' untranslated region (5' UTR).

The *IRF1* promoter is a paradigm for rapid, signal-dependent transcriptional activation. It lacks a canonical TATA box but contains multiple cis-regulatory elements, including:

- **STAT1-binding sites (GAS elements):** Located approximately -120 to -130 bp upstream of the transcription start site (TSS). These elements are bound by phosphorylated STAT1 homodimers following IFN-γ stimulation, providing the primary inducible transcriptional drive [2, 3].
- **ISRE-like elements:** Recognized by ISGF3 (STAT1-STAT2-IRF9 complex) in response to type I IFN signaling, allowing for secondary induction [2].
- **NF-κB binding sites:** Mediate induction by TNF-α, lipopolysaccharide (LPS), and DNA damage [4, 5].
- **IRF1 autoregulatory elements:** IRF1 can bind to its own promoter, establishing a positive feedback loop that amplifies and sustains expression [6].

### 1.2 Promoter Architecture and Epigenetic Regulation

The *IRF1* promoter is embedded within a CpG island, yet its basal methylation status is generally low, permitting rapid activation. However, dynamic histone modifications are critical for its regulation. Buro et al. (2010) demonstrated that IFN-γ-induced transcription of *IRF1* requires the coordinated recruitment of the menin tumor suppressor protein and the histone H2B ubiquitin ligase RNF20 [7]. Menin associates with the promoter and facilitates the recruitment of RNA polymerase II, while RNF20-mediated H2BK120 ubiquitination promotes chromatin remodeling and transcriptional elongation. Knockdown of menin disrupts this process, leading to reduced *IRF1* expression and impaired downstream ISG induction [7, 8]. Furthermore, Auriemma et al. (2012) showed that menin also influences pre-mRNA processing and promoter fidelity at the *IRF1* locus, suggesting a role in co-transcriptional splicing [8].

Chromatin accessibility at the *IRF1* promoter is dynamically regulated during macrophage differentiation and activation. Song et al. (2021) demonstrated that IRF1 itself governs the differential ISG responses in human monocytes and macrophages by regulating chromatin accessibility at thousands of genomic loci [9]. In monocytes, IRF1 binding is associated with the opening of enhancer elements that are inaccessible in macrophages, explaining the cell-type-specific differences in IFN responses. This work highlights IRF1 as a "pioneer-like" factor that can engage nucleosomal DNA and facilitate the recruitment of secondary transcription factors.

### 1.3 Enhancer Elements and Long-Range Interactions

Chromatin conformation capture studies have revealed that the *IRF1* promoter engages in long-range interactions with several distal enhancer elements. One notable enhancer is located approximately +85 kb downstream of the TSS, within the intron of the adjacent *IL5* gene. This enhancer is bound by STAT1 and IRF1 upon IFN-γ stimulation and is required for maximal *IRF1* induction in macrophages [10]. Abou El Hassan et al. (2018) performed ChIP-on-chip analysis and found that IRF1 binds extensively at remote intergenic elements without accompanying histone modifications, suggesting that IRF1 can occupy enhancers in a poised state prior to signal-dependent activation [10].

### 1.4 Alternative Splicing and Isoforms

The *IRF1* gene undergoes alternative splicing that generates multiple transcript variants. The canonical transcript (NM_002198.3) encodes the full-length 325-amino acid protein. However, several alternatively spliced isoforms have been documented:

- **IRF1-β (or IRF1b):** A splice variant that retains intron 7, resulting in a frameshift and premature termination. This isoform encodes a truncated protein lacking the C-terminal regulatory domain. IRF1-β can heterodimerize with full-length IRF1 and acts as a dominant-negative inhibitor, suppressing IRF1-mediated transcriptional activation.
- **IRF1-γ:** A variant lacking exon 3, which removes part of the DNA-binding domain. This isoform is expressed at low levels and may modulate IRF1 activity in a cell-type-specific manner.

The functional significance of these isoforms in human disease remains incompletely understood, but their existence adds a layer of regulatory complexity to IRF1 biology.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human IRF1 protein consists of 325 amino acids with a molecular weight of approximately 37.3 kDa. It is organized into three principal domains:

1. **N-terminal DNA-Binding Domain (DBD) (residues 1–113):** This domain adopts a characteristic helix-turn-helix motif that is conserved across the IRF family. It contains a tandem repeat of tryptophan residues that form a winged helix-turn-helix structure. The DBD recognizes the ISRE consensus sequence (5'-GAAAACTGAAAGT-3') and the GAS-like element (5'-TTTCNNTTTC-3'). The domain is composed of five α-helices and three β-strands, with the third helix (the "recognition helix") making base-specific contacts with the major groove of DNA [11].

2. **Central Linker Region (residues 114–220):** This region is less structured but contains nuclear localization signals (NLS) and sites for post-translational modification. The linker region is critical for interaction with coactivators such as CREB-binding protein (CBP)/p300 and for homo- or heterodimerization with other IRF family members.

3. **C-terminal Regulatory Domain (residues 221–325):** This domain mediates interactions with other transcription factors, including STAT1, NF-κB, and PU.1. It also contains the IRF-associated domain (IAD) that is responsible for protein-protein interactions. The C-terminus is subject to ubiquitination and proteasomal degradation, which is a major mechanism of IRF1 downregulation [12].

### 2.2 Structural Biology and DNA Recognition

High-resolution crystal structures of the IRF1 DBD bound to DNA have been solved for both the human and murine proteins. The DBD forms a symmetric homodimer on palindromic ISRE sequences, with each monomer contacting one half-site. The recognition helix (α3) inserts into the major groove, while the β-hairpin (wing) makes contacts with the minor groove. This bipartite interaction confers high-affinity binding (Kd ~ 1–10 nM) and sequence specificity.

The structure of the full-length IRF1 protein has been more challenging to obtain due to the intrinsic flexibility of the linker and C-terminal domains. However, low-resolution structures from small-angle X-ray scattering (SAXS) and cryo-electron microscopy (cryo-EM) of IRF1 in complex with DNA and coactivators have revealed that the protein undergoes a conformational change upon DNA binding, exposing surfaces for coactivator recruitment.

> **[Interactive 3D Protein Visualizer: Load IRF1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P10914)**

### 2.3 Post-Translational Modifications and Structural Consequences

IRF1 is subject to extensive post-translational modification that modulates its stability, localization, and activity:

- **Phosphorylation:** IRF1 is phosphorylated on multiple serine and threonine residues, primarily within the C-terminal domain. Phosphorylation by casein kinase II (CK2) enhances its transcriptional activity, while phosphorylation by protein kinase C (PKC) can promote nuclear export and degradation [1].
- **Ubiquitination:** IRF1 is a short-lived protein with a half-life of approximately 30–60 minutes. It is constitutively ubiquitinated by the E3 ligase UBE3A (E6-AP) and targeted for proteasomal degradation. In teleost fish, K63-linked ubiquitination of IRF1 by the TLR25/MyD88 pathway enhances its stability and transcriptional activity, whereas K48-linked ubiquitination promotes degradation [12]. In mammals, the deubiquitinase USP13 can remove ubiquitin moieties and stabilize IRF1.
- **SUMOylation:** IRF1 can be modified by SUMO1 or SUMO2/3 at lysine residues within the DBD. SUMOylation generally represses IRF1 transcriptional activity by promoting its nuclear retention in subnuclear foci and inhibiting its interaction with coactivators [2].
- **ADP-ribosylation:** PARP7 (TIPARP) catalyzes mono-ADP-ribosylation of IRF1, which inhibits its transcriptional activity and promotes cancer cell survival [3]. PARP7-mediated ADP-ribosylation of the transcription factor FRA1 also indirectly represses IRF1 expression, establishing a feed-forward oncogenic loop [3].

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The JAK-STAT-IRF1 Axis

The most well-characterized pathway leading to IRF1 induction is the JAK-STAT signaling cascade. Upon IFN-γ binding to its receptor (IFNGR1/IFNGR2), the receptor-associated kinases JAK1 and JAK2 are activated and phosphorylate STAT1 on tyrosine 701. Phosphorylated STAT1 forms homodimers that translocate to the nucleus and bind GAS elements in the *IRF1* promoter [2, 3]. This results in rapid and robust *IRF1* transcription, with mRNA levels peaking within 1–2 hours of stimulation.

IRF1 then functions as a secondary transcription factor, amplifying the IFN-γ signal by inducing a broad array of ISGs. This two-wave model of IFN-γ signaling (STAT1 → IRF1 → ISGs) is essential for the full expression of the IFN-γ transcriptome [2]. Ravi Sundar Jose Geetha et al. (2024) demonstrated that IRF1 and the ISGF3 complex (STAT1-STAT2-IRF9) dynamically control gene expression during IFN-β and IFN-γ signaling, with IRF1 playing a more prominent role in sustaining late-phase responses [2].

### 3.2 Type I and Type III Interferon Signaling

In response to type I IFNs (IFN-α/β), the ISGF3 complex (phosphorylated STAT1-STAT2 heterodimer associated with IRF9) binds ISRE elements and induces *IRF1* expression. However, the kinetics and magnitude of IRF1 induction differ between type I and type III IFNs (IFN-λ). Forero et al. (2019) showed that type I IFNs induce higher and more sustained IRF1 expression compared to type III IFNs, which correlates with the differential inflammatory responses elicited by these cytokines [4]. This differential IRF1 activation underlies the distinct immune responses to type I versus type III IFNs, with type I IFNs promoting stronger pro-inflammatory gene expression.

### 3.3 Toll-Like Receptor (TLR) Signaling

IRF1 is also induced by TLR signaling in a MyD88-dependent manner. TLR4 activation by LPS leads to the recruitment of MyD88 and the activation of NF-κB and IRF1. In teleost fish, a unique TLR25/MyD88 signaling axis promotes K63-linked ubiquitination of IRF1, enhancing its stability and nuclear translocation [12]. In mammalian macrophages, TLR4 signaling induces IRF1 expression through both NF-κB-dependent and -independent mechanisms [4]. IRF1 then cooperates with NF-κB to induce a subset of inflammatory genes, including IL-6, TNF-α, and iNOS [5].

### 3.4 IRF1 in Antigen Presentation and Immunogenicity

One of the most critical functions of IRF1 is the transcriptional regulation of the MHC class I antigen presentation pathway. IRF1 directly induces the expression of:

- **MHC class I heavy chain (HLA-A, -B, -C)**
- **β2-microglobulin (B2M)**
- **Transporter associated with antigen processing (TAP1, TAP2)**
- **Proteasome subunits (LMP2, LMP7, MECL1)**
- **NLRC5**, the master transcriptional regulator of MHC class I genes [6]

This coordinated induction is essential for the presentation of viral and tumor antigens to CD8+ T cells. Shen et al. (2017) found that genetic defects in the IRF1-mediated MHC class I pathway occur prevalently in the JAK2 gene in non-small cell lung cancer, leading to loss of antigen presentation and immune evasion [7]. SARS-CoV-2 has been shown to inhibit the STAT1-IRF1-NLRC5 axis, thereby suppressing MHC class I expression and evading cytotoxic T cell responses [6].

### 3.5 IRF1 in Cell Cycle Regulation and Apoptosis

IRF1 is a bona fide tumor suppressor that exerts its growth-suppressive effects through multiple mechanisms:

- **Cell Cycle Arrest:** IRF1 induces the expression of p21 (CDKN1A), which inhibits cyclin-dependent kinases and causes G1/S cell cycle arrest. It also represses the expression of cyclin D1 and cyclin E, further contributing to growth arrest.
- **Apoptosis:** IRF1 transcriptionally activates pro-apoptotic genes including CASP1, CASP8, and the death receptor ligand TRAIL. It also sensitizes cells to DNA damage-induced apoptosis by inducing the expression of the tumor suppressor p53 and its target genes [8].
- **Pyroptosis:** IRF1 is a key regulator of pyroptosis, a form of inflammatory programmed cell death mediated by caspase-1 and gasdermin D. IRF1 induces the expression of NLRP3, CASP1, and IL-1β, promoting pyroptotic cell death in various contexts [9, 10, 11, 12].
- **Ferroptosis:** Recent work by Chen et al. (2023) demonstrated that IRF1 suppresses colon cancer proliferation by reducing SPI1-mediated transcriptional activation of GPX4, thereby promoting ferroptosis [1].

### 3.6 IRF1 in Metabolic Regulation

Beyond its canonical immune functions, IRF1 plays a role in cellular metabolism. Alfarano et al. (2022) showed that IRF1 controls the metabolic programs of low-grade pancreatic cancer cells, regulating genes involved in oxidative phosphorylation, fatty acid oxidation, and glycolysis [2]. In adipocytes, IRF1 activation leads to phenotypes associated with metabolic disease, including impaired insulin signaling and increased inflammation [3]. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in multiple organs via IRF1, contributing to the metabolic abnormalities observed in COVID-19 patients [4].

### 3.7 Protein-Protein Interaction Networks

IRF1 engages in a complex network of protein-protein interactions that modulate its function:

| **Interacting Partner** | **Effect on IRF1 Function** | **Reference** |
|---|---|---|
| STAT1 | Cooperative DNA binding; IRF1 promotes STAT1 phosphorylation | [5, 6] |
| NF-κB (p65) | Synergistic activation of inflammatory genes | [4, 5] |
| Menin | Promotes chromatin remodeling and transcriptional elongation | [7, 8] |
| CBP/p300 | Histone acetyltransferase; promotes transcriptional activation | [3] |
| PU.1 | Cooperative regulation of myeloid-specific genes | [7] |
| IRF4 | Antagonistic regulation of target genes (e.g., IL-9) | [8, 9] |
| XAF1 | Stabilizes IRF1 protein and enhances antiviral immunity | [10] |
| PARP7 | ADP-ribosylation inhibits IRF1 activity | [3] |
| UBE3A | Ubiquitination and proteasomal degradation | [12] |

```mermaid
sequenceDiagram
    participant IFNγ as IFN-γ
    participant IFNGR as "IFN-γ Receptor"
    participant JAK as "JAK1/JAK2"
    participant STAT1 as "STAT1"
    participant IRF1 as "IRF1 Gene"
    participant IRF1p as "IRF1 Protein"
    participant ISG as "Interferon-Stimulated Genes"
    participant MHC as "MHC Class I Pathway"
    IFNγ->>IFNGR: Ligand binding
    IFNGR->>JAK: Receptor dimerization
    JAK->>STAT1: Phosphorylation (Y701)
    STAT1->>STAT1: Homodimerization
    STAT1->>IRF1: Nuclear translocation & GAS binding
    IRF1->>IRF1p: Transcription & translation
    IRF1p->>ISG: Binds ISRE elements
    IRF1p->>MHC: Induces TAP1, LMP2, NLRC5
    ISG->>MHC: Antigen presentation
    Note over IRF1p: IRF1 also induces its own expression (autoregulation)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

The *IRF1* gene is frequently deleted or inactivated in human cancers. Loss of heterozygosity (LOH) at the 5q23-q31 locus is observed in:

- **Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML):** Deletion of 5q is one of the most common cytogenetic abnormalities in these disorders. *IRF1* is a candidate tumor suppressor gene within the commonly deleted region.
- **Breast cancer:** Reduced IRF1 expression correlates with poor prognosis and resistance to chemotherapy.
- **Pancreatic ductal adenocarcinoma (PDAC):** IRF1 expression is lost in high-grade PDAC cells, contributing to their aggressive phenotype [2].
- **Colorectal cancer:** IRF1 suppresses proliferation and promotes ferroptosis; its loss is associated with metastasis [1, 11].
- **Melanoma:** IRF1 expression is inversely correlated with PD-L1 levels, and its loss contributes to immune evasion [1, 12].

### 4.2 Germline Polymorphisms and Disease Susceptibility

Several single nucleotide polymorphisms (SNPs) in the *IRF1* gene have been associated with disease susceptibility:

- **Celiac disease:** Seegers et al. (2003) investigated IL12B and IRF1 gene polymorphisms in celiac disease and found associations with disease susceptibility [2].
- **Tuberculosis:** Vollstedt et al. (2009) found no evidence for association between IRF1 gene polymorphisms and clinical tuberculosis in an Indonesian population [3].
- **Pig cytokine traits:** Liu et al. (2010) identified SNPs in the porcine IRF1 gene that affect cytokine traits, suggesting evolutionary conservation of IRF1 regulatory function [4].

### 4.3 Functional Mutations and Loss-of-Function Variants

While germline loss-of-function mutations in *IRF1* are rare, somatic mutations that disrupt its function have been identified:

- **Missense mutations in the DBD:** These mutations impair DNA binding and transcriptional activity. For example, mutations at residues R82 and R84, which contact DNA, abolish ISRE binding.
- **Nonsense mutations:** Premature stop codons in the DBD or linker region result in truncated proteins lacking the C-terminal regulatory domain.
- **Frameshift mutations:** Insertions or deletions that shift the reading frame and generate non-functional proteins.

### 4.4 IRF1 in Autoimmune and Inflammatory Diseases

IRF1 is a double-edged sword in autoimmunity. Its sustained activation contributes to chronic inflammation:

- **Systemic lupus erythematosus (SLE):** IRF1 marks activated genes in SLE monocytes and can induce target gene expression [5].
- **Rheumatoid arthritis (RA):** IRF1 is upregulated in the synovial lining of RA patients and contributes to the inflammatory milieu [6, 7].
- **Inflammatory bowel disease (IBD):** IRF1 is a key regulator of pyroptosis in intestinal epithelial cells in Crohn's disease [10].
- **Atherosclerosis:** IRF1 promotes vascular inflammation through the induction of VCAM-1 and other adhesion molecules [8, 9].
- **Atopic dermatitis:** IRF1 is a pyroptosis-related prognostic biomarker [12].

### 4.5 IRF1 in Neurodegeneration

IRF1 is involved in the regulation of microglial genes associated with neurodegeneration. Gao et al. (2019) identified IRF1 as a transcriptional regulator of disease-associated microglial (DAM) genes, suggesting a role in Alzheimer's disease and other neurodegenerative disorders [10]. IRF1 also mediates ischemia/reperfusion injury in the brain and retina [11, 12].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of IRF1-Mediated Immunity

Given its central role in antiviral defense, it is not surprising that many viruses have evolved mechanisms to evade or suppress IRF1 function:

- **SARS-CoV-2:** The virus inhibits the STAT1-IRF1-NLRC5 axis, suppressing MHC class I antigen presentation and evading CD8+ T cell responses [6]. SARS-CoV-2 also impairs insulin/IGF signaling via IRF1, contributing to metabolic dysfunction [4].
- **Influenza A virus (H1N1):** MicroRNA-132-3p suppresses type I IFN responses by targeting IRF1, facilitating viral infection [1].
- **Herpes simplex virus 1 (HSV-1):** MicroRNA-373 facilitates HSV-1 replication by suppressing type I IFN responses through targeting IRF1 [2].
- **Epstein-Barr virus (EBV):** IRF1 and IRF2 constitutively activate EBV nuclear antigen 1 (EBNA1) gene transcription during restricted EBV latency [3].
- **Bovine viral diarrhea virus (BVDV-1):** BVDV-1 induces IFN-β gene expression through a pathway involving IRF1, IRF7, and NF-κB activation [4].
- **Classical swine fever virus (CSFV):** IRF1 upregulates ISG15 gene expression during CSFV infection [5].

### 5.2 Bacterial and Parasitic Infections

IRF1 also plays a critical role in antibacterial and antiparasitic immunity:

- **Mycobacterium tuberculosis:** IRF1 is a potential biomarker in M. tuberculosis infection [6]. MicroRNA-23a-3p downregulation in active pulmonary TB patients inhibits mononuclear cell function via targeting IRF1/SP1 [7].
- **Leishmania infantum:** TLR4 abrogates the Th1 immune response through IRF1 and IFN-β to prevent immunopathology during L. infantum infection [8].
- **Bacterial infections:** The canonical antiviral protein OAS1 elicits antibacterial functions by enhancing IRF1 translation [9].

### 5.3 IRF1 in Bat Immunity

Bats are natural reservoirs for many zoonotic viruses and exhibit elevated basal expression of antiviral genes. Irving et al. (2020) showed that IRF1, IRF3, and IRF7 levels are elevated in most bat tissues and contribute to the constitutive expression of type I IFN and ISGs [10]. Functional characterization of bat IRF1 revealed that it can induce IFN-β production, suggesting that bats have evolved a unique IRF1-dependent antiviral state that allows them to control viral replication without overt inflammation [11].

### 5.4 IRF1 in Aging and Antiviral Responses

Aging is associated with impaired antiviral immune responses. Li et al. (2025) demonstrated that IRF1-RIG-I signaling defects in aged alveolar epithelial cells contribute to decreased pulmonary antiviral immune responses [12]. This age-related decline in IRF1 function may explain the increased susceptibility of elderly individuals to severe respiratory viral infections, including COVID-19.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 IRF1 as a Therapeutic Target

The dual role of IRF1 in tumor suppression and inflammation makes it an attractive but challenging therapeutic target. Strategies to modulate IRF1 activity include:

- **IRF1 activation for cancer therapy:** Enhancing IRF1 expression or activity could restore tumor suppressor functions and improve antitumor immunity. Approaches include:
  - **IFN-γ therapy:** Recombinant IFN-γ has been used clinically to induce IRF1 expression and enhance antigen presentation.
  - **HDAC inhibitors:** Histone deacetylase inhibitors (e.g., vorinostat, romidepsin) can epigenetically reactivate IRF1 expression.
  - **PARP7 inhibitors:** RBN-2397 and other PARP7 inhibitors have shown antitumor activity by relieving PARP7-mediated repression of IRF1 and IRF3 [3].
  - **Nur77 agonists:** The Nur77-IRF1 axis inhibits esophageal squamous cell carcinoma growth and improves anti-PD-1 treatment efficacy [1].

- **IRF1 inhibition for inflammatory diseases:** Suppressing IRF1 activity could ameliorate chronic inflammation. Approaches include:
  - **Antisense oligonucleotides (ASOs):** ASOs targeting IRF1 mRNA have been explored in preclinical models.
  - **Small-molecule inhibitors:** Compounds that disrupt IRF1 DNA binding or protein-protein interactions are under development.
  - **miRNA-based therapies:** MicroRNAs that target IRF1 (e.g., miR-373, miR-132-3p, miR-1226-5p) could be used to suppress IRF1 expression [1, 2].

### 6.2 Pharmacogenomic Considerations

Genetic polymorphisms in *IRF1* may influence responses to immunotherapy. For example, IRF1 expression is a biomarker of CD8+ T cell infiltration in cutaneous melanoma, and patients with high IRF1 expression may benefit more from immune checkpoint inhibitors [1]. Conversely, loss of IRF1 function is associated with resistance to IFN-based therapies.

### 6.3 Drug Repurposing Opportunities

Several FDA-approved drugs have been shown to modulate IRF1 expression:

- **Dimethyl fumarate (DMF):** Used for relapsing-remitting multiple sclerosis, DMF affects NRF2, NF-κB, and IRF1 pathway genes [3].
- **Statins:** Some statins have been shown to modulate IRF1 expression in vascular cells.
- **Metformin:** The antidiabetic drug metformin can influence IRF1-mediated inflammatory responses.

### 6.4 Gene Therapy Vectors

CRISPR-based gene editing approaches to restore IRF1 function in cancers with IRF1 loss are in preclinical development. Additionally, viral vectors expressing IRF1 have been explored for cancer gene therapy.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 3659 | Gene ID for human IRF1 |
| **Ensembl** | ENSG00000125347 | Ensembl gene ID |
| **UniProt** | P10914 | Protein accession |
| **RCSB PDB** | 1IRF, 2IRF, 3IRF | Crystal structures of IRF1 DBD |
| **OMIM** | 147575 | Online Mendelian Inheritance in Man |
| **HGNC** | 6116 | HUGO Gene Nomenclature Committee |
| **GeneCards** | GC05M132481 | GeneCards entry |
| **ClinVar** | Various | Clinical variants |
| **COSMIC** | Various | Somatic mutations in cancer |
| **STRING** | 9606.ENSP00000358429 | Protein-protein interaction network |
| **BioGRID** | 109216 | Protein interaction database |
| **Gene Ontology (GO)** | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0006355 (regulation of transcription) | Functional annotations |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Li, Y., Yi, S., Tang, W., Shi, L., Yan, H., Ning, L., Pu, J., Shiyi, K., Zhang, L., Chen, X., Wu, J., Yang, S., Zeng, X.-L., & Du, X. (2025). Teleost-specific TLR25/MyD88 signaling promotes K63-linked ubiquitination of IRF1 to induce IFNa gene expression. *Fish and Shellfish Immunology*. https://www.semanticscholar.org/paper/1f425ff9f69b0167f4a84ba421ac7ed3bcf23293

[2] Buro, L. J., Chipumuro, E., & Henriksen, M. A. (2010). Menin and RNF20 recruitment is associated with dynamic histone modifications that regulate signal transducer and activator of transcription 1 (STAT1)-activated transcription of the interferon regulatory factor 1 gene (IRF1). *Epigenetics & Chromatin*. https://www.semanticscholar.org/paper/b560d5e172787759d865bb1d97e334754818aba6

[3] Ravi Sundar Jose Geetha, A., Fischer, K., Babadei, O., Smesnik, G., Vogt, A., Platanitis, E., Müller, M., Farlik, M., & Decker, T. (2024). Dynamic control of gene expression by ISGF3 and IRF1 during IFNβ and IFNγ signaling. *EMBO Journal*. https://www.semanticscholar.org/paper/59905239feee02ab326f6e263d1eb6f89e90f8e1

[4] Martinková, L., Zatloukalová, P., Kučeríková, M., Friedlová, N., Tylichová, Z., Zavadil-Kokas, F., Hupp, T., Coates, P. J., & Vojtěšek, B. (2024). Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis. *Cellular & Molecular Biology Letters*. https://www.semanticscholar.org/paper/24d7c0ff7ce02c7e462b4c7087d6cd5ecdeab61b

[5] Itoh, S., Harada, H., Nakamura, Y., Nakamura, Y., White, R., White, R., & Taniguchi, T. (1991). Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23-q31. *Genomics*. https://www.semanticscholar.org/paper/e15dd217bb5a458907edf2765059e173e46daef3

[6] Seegers, D., Borm, M., van Belzen, M. V., Mulder, C. J. J., Bailing, J., Crusius, J., Meijer, J. W. R., Wijmenga, C., Peña, A. S., & Bouma, G. (2003). IL12B and IRF1 gene polymorphisms and susceptibility to celiac disease. *European Journal of Immunogenetics*. https://www.semanticscholar.org/paper/33dbefb0a54d54068d33a58ceb51867ac112eae5

[7] Auriemma, L. B., Shah, S., Linden, L. M., & Henriksen, M. A. (2012). Knockdown of menin affects pre-mRNA processing and promoter fidelity at the interferon-gamma inducible IRF1 gene. *Epigenetics & Chromatin*. https://www.semanticscholar.org/paper/3108359afb92790e4c048552de1ecbe4d0db5f44

[8] Vollstedt, S., Yuliwulandari, R., Okamoto, K., Lien, L. T., Keicho, N., Rochani, J. T., Wikaningrum, R., & Tokunaga, K. (2009). No evidence for association between the interferon regulatory factor 1 (IRF1) gene and clinical tuberculosis. *Tuberculosis*. https://www.semanticscholar.org/paper/98846f3fa86f24939b8844afd24109ebb6d5ce0b

[9] Liu, Y.-S., Lu, X., Luo, Y., Zhou, J., Liu, X., Zhang, Q., & Yin, Z. (2010). Effect of single nucleotide polymorphism of IRF1 gene on cytokine traits in three pig breeds. *Scientific Publication*. https://www.semanticscholar.org/paper/6251ed7aebdb97b4fe157ceb68319d89055c7e29

[10] Song, R., Gao, Y., Dozmorov, I., Malladi, V., Saha, I., McDaniel, M. M., Parameswaran, S., Liang, C., Arana, C., Zhang, B., Wakeland, B., Zhou, J., Weirauch, M., Kottyan, L. C., Wakeland, E., & Pasare, C. (2021). IRF1 governs the differential interferon-stimulated gene responses in human monocytes and macrophages by regulating chromatin accessibility. *Cell Reports*. https://www.semanticscholar.org/paper/c20fc5e6abd2ce492718e737c0d77f25069cce15

[11] Kroef, M., Williemze, R., & Landegent, J. E. (1993). Dinucleotide repeat polymorphism in the interferon regulating factor 1 (IRF1) gene. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/41f8b9483419758d495a6235190f86d6d1347866

[12] Zhao, J., Gao, S., Guo, Y., Xu, Q., Liu, M., Zhang, C., Cheng, M